159 related articles for article (PubMed ID: 38272301)
1. A review on potential therapeutic targets for the treatment of leishmaniasis.
Sheikh SY; Hassan F; Shukla D; Bala S; Faruqui T; Akhter Y; Khan AR; Nasibullah M
Parasitol Int; 2024 Jun; 100():102863. PubMed ID: 38272301
[TBL] [Abstract][Full Text] [Related]
2. Genome wide comparison of Leishmania donovani strains from Indian visceral leishmaniasis and para-kala-azar dermal leishmaniasis patients.
Sarraf NR; Mukhopadhyay S; Banerjee A; Das AK; Roy S; Chakrabarti S; Manna M; Saha P
Acta Trop; 2021 Nov; 223():106086. PubMed ID: 34389331
[TBL] [Abstract][Full Text] [Related]
3. PKDL and other dermal lesions in HIV co-infected patients with Leishmaniasis: review of clinical presentation in relation to immune responses.
Zijlstra EE
PLoS Negl Trop Dis; 2014; 8(11):e3258. PubMed ID: 25412435
[TBL] [Abstract][Full Text] [Related]
4. Relapse after treatment with miltefosine for visceral leishmaniasis is associated with increased infectivity of the infecting Leishmania donovani strain.
Rai K; Cuypers B; Bhattarai NR; Uranw S; Berg M; Ostyn B; Dujardin JC; Rijal S; Vanaerschot M
mBio; 2013 Oct; 4(5):e00611-13. PubMed ID: 24105765
[TBL] [Abstract][Full Text] [Related]
5. Post-kala-azar dermal leishmaniasis in the Indian subcontinent: A threat to the South-East Asia Region Kala-azar Elimination Programme.
Zijlstra EE; Alves F; Rijal S; Arana B; Alvar J
PLoS Negl Trop Dis; 2017 Nov; 11(11):e0005877. PubMed ID: 29145397
[TBL] [Abstract][Full Text] [Related]
6. Review on the Drug Intolerance and Vaccine Development for the Leishmaniasis.
Kumari P; Mamud A; Jha AN
Curr Drug Targets; 2023; 24(13):1023-1031. PubMed ID: 37823567
[TBL] [Abstract][Full Text] [Related]
7. Leishmanin and tuberculin sensitivity in leishmaniasis in the Sudan, with special reference to kala-azar.
Zijlstra EE; el-Hassan AM
Trans R Soc Trop Med Hyg; 1993; 87(4):425-7. PubMed ID: 8249072
[TBL] [Abstract][Full Text] [Related]
8. An In-depth Proteomic Map of Leishmania donovani Isolate from Post Kala-azar Dermal Leishmaniasis (PKDL) Patient.
Routaray CB; Kumar A; Sundar S; Sathe G; Pawar H; Pai K
Acta Parasitol; 2022 Jun; 67(2):687-696. PubMed ID: 35020128
[TBL] [Abstract][Full Text] [Related]
9. In vitro growth of Leishmania parasites from biopsy samples of suspected cutaneous and visceral leishmaniasis cases in Sri Lanka: An observational study.
Deepachandi B; Weerasinghe S; Gunathileka H; Soysa P; Siriwardana Y
Exp Parasitol; 2024 Apr; 259():108710. PubMed ID: 38350521
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of Immunopathogenesis in Cutaneous Leishmaniasis And Post Kala-azar Dermal Leishmaniasis (PKDL).
Volpedo G; Pacheco-Fernandez T; Holcomb EA; Cipriano N; Cox B; Satoskar AR
Front Cell Infect Microbiol; 2021; 11():685296. PubMed ID: 34169006
[TBL] [Abstract][Full Text] [Related]
11. DNA polymorphism assay distinguishes isolates of Leishmania donovani that cause kala-azar from those that cause post-kala-azar dermal Leishmaniasis in humans.
Sreenivas G; Raju BV; Singh R; Selvapandiyan A; Duncan R; Sarkar D; Nakhasi HL; Salotra P
J Clin Microbiol; 2004 Apr; 42(4):1739-41. PubMed ID: 15071036
[TBL] [Abstract][Full Text] [Related]
12. Post-kala-azar dermal leishmaniasis in visceral leishmaniasis-endemic communities in Bihar, India.
Singh RP; Picado A; Alam S; Hasker E; Singh SP; Ostyn B; Chappuis F; Sundar S; Boelaert M
Trop Med Int Health; 2012 Nov; 17(11):1345-8. PubMed ID: 22882665
[TBL] [Abstract][Full Text] [Related]
13. Experimental structure based drug design (SBDD) applications for anti-leishmanial drugs: A paradigm shift?
Marín M; López M; Gallego-Yerga L; Álvarez R; Peláez R
Med Res Rev; 2024 May; 44(3):1055-1120. PubMed ID: 38142308
[TBL] [Abstract][Full Text] [Related]
14. Cutaneous and mucocutaneous leishmaniasis: Clinical perspectives.
Handler MZ; Patel PA; Kapila R; Al-Qubati Y; Schwartz RA
J Am Acad Dermatol; 2015 Dec; 73(6):897-908; quiz 909-10. PubMed ID: 26568335
[TBL] [Abstract][Full Text] [Related]
15. Post-kala-azar dermal leishmaniasis in a patient treated with injectable paromomycin for visceral leishmaniasis in India.
Pandey K; Das VN; Singh D; Das S; Lal CS; Verma N; Bimal S; Topno RK; Siddiqui NA; Verma RB; Sinha PK; Das P
J Clin Microbiol; 2012 Apr; 50(4):1478-9. PubMed ID: 22278840
[TBL] [Abstract][Full Text] [Related]
16. Road-map of pre-clinical treatment for Visceral Leishmaniasis.
Mazire P; Agarwal V; Roy A
Drug Dev Res; 2022 Apr; 83(2):317-327. PubMed ID: 34962315
[TBL] [Abstract][Full Text] [Related]
17. Recurrent leishmaniasis in kidney transplant recipients: report of 2 cases and systematic review of the literature.
Simon I; Wissing KM; Del Marmol V; Antinori S; Remmelink M; Nilufer Broeders E; Nortier JL; Corbellino M; Abramowicz D; Cascio A
Transpl Infect Dis; 2011 Aug; 13(4):397-406. PubMed ID: 21281418
[TBL] [Abstract][Full Text] [Related]
18. Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis.
Bhandari V; Kulshrestha A; Deep DK; Stark O; Prajapati VK; Ramesh V; Sundar S; Schonian G; Dujardin JC; Salotra P
PLoS Negl Trop Dis; 2012; 6(5):e1657. PubMed ID: 22629478
[TBL] [Abstract][Full Text] [Related]
19. Visceral and post-Kala-Azar dermal leishmaniasis isolates show significant difference in their in vitro drug susceptibility pattern.
Mishra J; Madhubala R; Singh S
Parasitol Res; 2013 Mar; 112(3):1001-9. PubMed ID: 23242321
[TBL] [Abstract][Full Text] [Related]
20. The leishmaniases in Kenya: A scoping review.
Grifferty G; Shirley H; O'Brien K; Hirsch JL; Orriols AM; Amechi KL; Lo J; Chanda N; El Hamzaoui S; Kahn J; Yap SV; Watson KE; Curran C; Atef AbdelAlim A; Bose N; Cilfone AL; Wamai R
PLoS Negl Trop Dis; 2023 Jun; 17(6):e0011358. PubMed ID: 37262045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
